Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant...

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Bacteriophage-derived lysins represent a new class of anti-infective agents.
• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in healthcare settings, particularly in bone infections like osteomyelitis.
• Novel therapeutic strategies are urgently needed to combat antibiotic-resistant bacterial infections.

Purpose of the Study:

• To evaluate the efficacy of exebacase (CF-301), a bacteriophage-derived lysin, as a monotherapy and in combination with daptomycin against MRSA osteomyelitis.
• To compare the antibacterial activity of exebacase and daptomycin, alone and in combination, in an established rat model of acute osteomyelitis.

Main Methods:

• An acute osteomyelitis model was established in rats using methicillin-resistant Staphylococcus aureus (MRSA).
• Animals were assigned to treatment groups: no treatment, daptomycin alone, exebacase (CF-301) alone, or daptomycin plus exebacase.
• Bacterial burden in bone was quantified as log10 CFU/gram at the study endpoint.

Main Results:

• All treatment groups demonstrated a significant reduction in bacterial CFU/gram compared to untreated controls (P ≤ 0.0001).
• Combination therapy with daptomycin plus exebacase resulted in the lowest mean bacterial load (3.57 log10 CFU/gram).
• The combination therapy was significantly more effective than daptomycin alone (P = 0.0042) and exebacase alone (P < 0.001).

Conclusions:

• Exebacase, alone or in combination with daptomycin, exhibits potent antibacterial activity against MRSA in an osteomyelitis model.
• Combination therapy of daptomycin and exebacase offers superior efficacy in reducing MRSA burden in bone infections.
• These findings support the further development of exebacase as a therapeutic agent for MRSA infections, particularly osteomyelitis.